Management of Symptomatic Syncope in Brugada Syndrome
Initial Assessment and Stabilization
- The American College of Cardiology recommends admitting the patient immediately to a monitored bed with continuous telemetry and preparing for ICD evaluation, as syncope in Brugada syndrome is presumed arrhythmic until proven otherwise 1, 2, 3
- Obtain 12-lead ECG with high electrode positioning to confirm spontaneous type 1 Brugada pattern: coved ST-segment elevation ≥2 mm in V1 and/or V2 with negative T-waves 3, 4
- Check temperature and treat fever aggressively with antipyretics if present, as fever can acutely precipitate cardiac arrest in Brugada syndrome 3, 4, 5
- Review all medications immediately and discontinue sodium channel blockers, QT-prolonging drugs, psychotropic agents, and anesthetic agents that may trigger ventricular fibrillation 3, 4, 5
Risk Stratification and Disposition
- The American Heart Association recommends ICD implantation if meaningful survival greater than 1 year is expected, as this is the only proven therapy to prevent sudden cardiac death 1, 3, 7
- The annual arrhythmic event rate in Brugada patients with syncope is 3.2% compared to 13.5% in cardiac arrest survivors and 1% in asymptomatic patients 4, 5
Definitive Management Plan
- ICD implantation is recommended for patients with spontaneous type 1 ECG pattern and syncope presumed due to ventricular arrhythmia 1, 3, 7
- Quinidine is a Class I recommendation for patients who decline or are not candidates for ICD 1, 3, 7
- Catheter ablation of right ventricular outflow tract may be considered as an alternative option 1, 3, 7